Drug Type Small molecule drug |
Synonyms niraparib, niraparib hydrochloride, Niraparib Tosilate + [14] |
Target |
Action inhibitors |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Mar 2017), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (South Korea), Conditional marketing approval (China) |
Molecular FormulaC26H30N4O5S |
InChIKeyACNPUCQQZDAPJH-FMOMHUKBSA-N |
CAS Registry1613220-15-7 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10140 | Niraparib Tosylate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Recurrent Primary Peritoneal Carcinoma | United States | 27 Mar 2026 | |
| BRCA-mutated Ovarian Cancer | United States | 23 Oct 2019 | |
| Ovarian Cancer | United Kingdom | 16 Nov 2017 | |
| Peritoneal Neoplasms | United Kingdom | 16 Nov 2017 | |
| Platinum-sensitive epithelial ovarian cancer | European Union | 16 Nov 2017 | |
| Platinum-sensitive epithelial ovarian cancer | Iceland | 16 Nov 2017 | |
| Platinum-sensitive epithelial ovarian cancer | Liechtenstein | 16 Nov 2017 | |
| Platinum-sensitive epithelial ovarian cancer | Norway | 16 Nov 2017 | |
| Platinum-Sensitive Fallopian Tube Carcinoma | European Union | 16 Nov 2017 | |
| Platinum-Sensitive Fallopian Tube Carcinoma | Iceland | 16 Nov 2017 | |
| Platinum-Sensitive Fallopian Tube Carcinoma | Liechtenstein | 16 Nov 2017 | |
| Platinum-Sensitive Fallopian Tube Carcinoma | Norway | 16 Nov 2017 | |
| Platinum-Sensitive Primary Peritoneal Carcinoma | European Union | 16 Nov 2017 | |
| Platinum-Sensitive Primary Peritoneal Carcinoma | Iceland | 16 Nov 2017 | |
| Platinum-Sensitive Primary Peritoneal Carcinoma | Liechtenstein | 16 Nov 2017 | |
| Platinum-Sensitive Primary Peritoneal Carcinoma | Norway | 16 Nov 2017 | |
| Fallopian Tube Carcinoma | United States | 27 Mar 2017 | |
| Ovarian Epithelial Carcinoma | United States | 27 Mar 2017 | |
| Primary peritoneal carcinoma | United States | 27 Mar 2017 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| BRCA Mutation Castration-Resistant Prostate Cancer | NDA/BLA | European Union | 27 Feb 2023 | |
| Glioblastoma Multiforme | Phase 3 | United States | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Australia | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Canada | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | France | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Germany | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Italy | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Netherlands | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Norway | 19 Jun 2024 | |
| Glioblastoma Multiforme | Phase 3 | Spain | 19 Jun 2024 |
Phase 3 | Non-Small Cell Lung Cancer Maintenance | 666 | cbnyfltqpp(jeoowrdyca) = ewsohygxkb cktfdxfrox (crrgctdpfa ) | Negative | 01 Nov 2026 | ||
Placebo-plus-Pembrolizumab | cbnyfltqpp(jeoowrdyca) = iqxironbhs cktfdxfrox (crrgctdpfa ) | ||||||
Phase 2 | 67 | Niraparib 200 mg or 300 mg | vxifwelaig(uzmzxrqlyz) = qluyutsdeh lslnnudwtt (rpjwecdwrc, 64 - 91) View more | Positive | 01 Nov 2026 | ||
Not Applicable | 56 | ycxmqzmcsb(hhfwndoetk) = jhertjiwuq ihozzvhlif (waqomdgrvn, 7.3 - 52.7) | Positive | 23 Oct 2026 | |||
(HRD-negative) | ycxmqzmcsb(hhfwndoetk) = ljafdsully ihozzvhlif (waqomdgrvn, 0 - 32.8) View more | ||||||
Phase 3 | Prostate Cancer, Familial BRCA1/2 | 229 | hvgzszzeef(vszbkvimkd) = yuuzugbput hpavfezzzb (hiajadlkxw, 93.8 - 100) View more | Positive | 23 Oct 2026 | ||
- | |||||||
Phase 2 | Metastatic castration-resistant prostate cancer HRR alterations | BRCA1/2 alterations | TP53 mutations ... View more | 99 | rvswkwrajg(ibnnuuryev) = aqkebaibql sfgnerqowe (rrvvdjgpny ) View more | Positive | 23 Oct 2026 | ||
Standard of Care (SOC) | rvswkwrajg(ibnnuuryev) = vkbbythisi sfgnerqowe (rrvvdjgpny ) View more | ||||||
Phase 2 | Advanced cancer BRCA1/2 | ATM | HRD | 46 | uefbzecksi(czderdcxhh) = yytoqewtvw wdjjujrgjg (aynnloreyg ) View more | Negative | 23 Oct 2026 | ||
(BRCA1/2) | uefbzecksi(czderdcxhh) = qqwjlabpaf wdjjujrgjg (aynnloreyg ) View more | ||||||
Not Applicable | Ovarian Cancer First line | Maintenance | 134 | fvecksxupg(btjdlsiptd) = ietcfltois fzvntpefpu (swtharrhwb ) View more | Positive | 23 Oct 2026 | ||
fvecksxupg(btjdlsiptd) = dcijbomktd fzvntpefpu (swtharrhwb ) View more | |||||||
Not Applicable | Platinum-Sensitive Ovarian Carcinoma Maintenance | 159 | Niraparib maintenance therapy | ilmiojdpey(yixosjlgxw) = The incidence of grade ≥3 hematologic toxicities was 10.7% for thrombocytopenia, 17.0% for anemia, and 11.9% for neutropenia. shbbbszsnl (gyifwbqrjd ) View more | Positive | 01 Oct 2026 | |
Not Applicable | 94 | (BRCA-mutated) | jkdlksmnue(pjwutibkap) = jbtugvqjpw devewhpcoe (wgipdcuigq ) View more | Positive | 01 Oct 2026 | ||
(BRCA-wildtype) | jkdlksmnue(pjwutibkap) = rdwcyjbweo devewhpcoe (wgipdcuigq ) View more | ||||||
Phase 3 | Glioblastoma MGMT-unmethylated | 450 | percxrrigo(qsflizivnr) = ovrjymxedr bptqfotmgg (prhutejqnk ) | Positive | 24 Sep 2026 | ||
percxrrigo(qsflizivnr) = rxehlkiyfz bptqfotmgg (prhutejqnk ) View more |





